Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSource CoTSE:4880 -1.15%69 PS Ratio is 1.87 as of Jul. 16, 2026, which is 81% below its 10-year median of 10.06. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円780.88 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 930 Biotechnology companies, CellSource Co ranks better than 85.81% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CellSource Co's share price is 円345.00.
CellSource Co's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was 円184.71. Hence, CellSource Co's PS Ratio for today is 1.87.
The historical rank and industry rank for CellSource Co's PS Ratio or its related term are showing as below:
TSE:4880'
s PS Ratio Range Over the Past 10 Years
Min: 1.61 Med: 10.06 Max: 68.14
Current: 1.88
During the past 9 years, CellSource Co's highest PS Ratio was 68.14. The lowest was 1.61. And the median was 10.06.
TSE:4880's PS Ratio is ranked better than 85.81% of 930
companies
in the Biotechnology industry
Industry Median: 9.655
vs TSE:4880: 1.88
CellSource Co Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of CellSource Co was -7.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -5.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 13.50% per year.
During the past 9 years, CellSource Co's highest 3-Year average Revenue per Share Growth Rate was 47.80% per year. The lowest was -5.60% per year. And the median was 19.65% per year.
Back to Basics: PS Ratio
CellSource Co (TSE:4880) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
CellSource Co PS Ratio Related Terms
CellSource Co PS Ratio Historical Data
* Premium members only.
The historical data trend for CellSource Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CellSource Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where CellSource Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CellSource Co's Share Price of today is 円345.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was 円184.71.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
CellSource Co (TSE:4880) has a PS Ratio of 1.87 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CellSource Co and its competitors. This is 81% below median its historical median of 10.06. Over the past decade, CellSource Co's PS Ratio has ranged from 1.61 to 68.14. According to the industry distribution chart, CellSource Co ranks #132 out of 930 companies in the Biotechnology industry, placing it in the top 14.2%.
Is CellSource Co's PS Ratio too high?
CellSource Co's current PS Ratio of 1.87 is 81% below median its 10-year median of 10.06. Over the past 10 years, this metric has ranged from a low of 1.61 to a high of 68.14. The Biotechnology industry median PS Ratio is 9.66. CellSource Co's value of 1.87 is 80.6% below this industry median. Based on the distribution chart, CellSource Co ranks #132 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #132 out of 930 companies for PS Ratio. This places CellSource Co in the top 14% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.66. CellSource Co's value of 1.87 is 80.6% below this benchmark. Historically, CellSource Co's own PS Ratio has ranged from 1.61 to 68.14 over the past decade. While the company's 10-year median is 10.06 vs. the industry median of 9.66, CellSource Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current PS Ratio of 1.87 is 80.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CellSource Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current PS Ratio is 1.87, which is 81% below median its own 10-year median of 10.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円780.88, compared to a current price of 円345.00 — trading 55.8% below its estimated fair value. The current PS Ratio is 1.87, which is 81% below median its 10-year median of 10.06 and 80.6% below the Biotechnology industry median of 9.66. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current PS Ratio is 1.87 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円345.00 is trading 55.8% below its estimated GF Value™ of 円780.88.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
PS Ratio: 1.87 (81% below median its 10-year median of 10.06)
GF Value™: 円780.88 vs. price of 円345.00 (55.8% below fair value)
Industry Position: 80.6% below the Biotechnology median (#132 of 930)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
